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Functional gastrointestinal symptoms in patients with IBD
The gastrointestinal tract can only express itself in limited ways, such as abdominal pain, altered bowel habits, and bloating. The symptoms of inflammatory bowel disease (IBD) do share similarities with those of irritable bowel syndrome (IBS) or other functional gastrointestinal disorders. Indeed, in patients with IBD in whom the disease is quiescent (referring to no or only low-grade inflammation), IBS-like symptoms are present in over 30%, irrespective of whether the underlying diagnosis is Crohn's disease or ulcerative colitis. 1 In patients with IBD, concurrent IBS confers a significantly worse quality of life, 2,3 so intervention is warranted. Many studies have looked more closely at this patient group to determine what proportion of patients has inflammatory activity and what proportion is in actual remission using endoscopic appearance or fecal calprotectin. [4] [5] [6] The clinical problem, however, is defining the "cut-off" between active disease inducing the symptoms and remission with symptoms that are functional, because therapeutic approaches are quite different. The decision is not difficult in most patients, but the problem arises when the symptoms seem out of step with the inflammatory state. Ideally, optimization of anti-inflammatory therapy is important if residual inflammation is present, but care needs to be exercised in not over-treating the patient. The whole question of functional versus inflammatory symptoms has become more important since the development of better strategies to deal with functional symptoms, extrapolating from patients with IBS. One important strategy is diet to improve functional symptoms.
Gluten-free diet in IBD
The most common diet used for symptom relief in patients with IBD is a gluten-free diet. North American surveys indicated 8% of patients actively used a gluten-free diet to control symptoms. 7 In the UK, 28% of a cohort of 145 patients with IBD believed they were gluten-sensitive, and 6% were gluten-free. 8 The only prospective interventional study reported, however, is from 1965 in patients with ulcerative colitis; patients were unable to adhere to the diet. 9 Hence, the level of evidence for efficacy of a gluten-free diet in patients with IBD is poor.
Low-FODMAP diet and IBD
The low-FODMAP diet has had a big impact in patients with IBS, and it has received considerable interest in its application to those with IBD. There are four aspects to consider.
FODMAP intake by patients with IBD. Utilizing the "CNAQ," a food frequency questionnaire validated to assess FODMAP intake 10 , James showed wide variations in intake of all FODMAPs with no differences across ulcerative colitis (n = 64), Crohn's disease (n = 57), and healthy controls (n = 72). 11 There were no differences if a quartile analysis was performed for FODMAPs or for dietary fiber. No difference was seen according to the degree of disease activity. A casecontrol study from King's College London identified a significantly lower mean fructan intake in patients with Crohn's disease and lower intake in those with active versus quiescent disease. 12 Whether this low intake of fructan was cause or effect remains to be ascertained.
The ability of patients with IBD to absorb a load of fructose or to digest lactose. In a large cohort of Caucasian patients having breath hydrogen tests after lactose (50 g), lactose malabsorption was found in over 40% of patients with Crohn's disease (n = 92) or ulcerative colitis (n = 56) compared with half that proportion in healthy controls (n = 83) and in those with functional gastrointestinal disorders (n = 201). 13 Fructose malabsorption (after a dose of 35 g) was significantly more common in patients with Crohn's disease (61%) compared with the comparator populations (33-44%). This was not related to rapid small intestinal transit or intestinal resection. Thus, there is greater exposure of the distal small bowel and proximal colon to fructose in Crohn's disease and to lactose in IBD in general, with greater potential for inducing symptoms from their osmotic and fermentative effects. Unfortunately, that study did not relate gastrointestinal symptoms of individuals to their carbohydrate absorptive profiles.
Impact of lowering FODMAP intake on gastrointestinal symptoms in patients with IBD. Observational studies have strongly suggested efficacy for restriction of FODMAPs for presumed functional abdominal symptoms in patients with quiescent IBD. In a retrospective telephone survey of 72 patients with IBD (52 Crohn's disease, 20 ulcerative colitis) and functional gut symptoms who received low-FODMAP dietary advice at least 3 months prior from a specialized gastroenterology dietitian, 14 56% had clinically significant improvement overall abdominal symptoms, abdominal pain, bloating, wind, and diarrhea improved in all IBD patients (P < 0.02). More recently, Prince et al. conducted a prospective case-note review of electronic medical records of patients with IBD from a single UK tertiary center. 15 Eighty-eight patients with IBD (39 Crohn's disease, 38 ulcerative colitis, 11 IBD unclassified) were advised to follow a diet low in FODMAPs for a minimum 6 weeks by a specialized gastroenterology dietitian. There was a significant decrease in the severity of most symptoms and composite symptom score (P < 0.001) as well as significant improvements in stool consistency (P = 0.002) and frequency (P < 0.001). Similar positive findings in symptomatic patients with IBD have been reported from Denmark. 16 In a small study of patients without a colon (ileorectal anastomosis or ileal pouch), efficacy of lowering FODMAP intake was apparent. 17 These results are very promising, but without a control group, the placebo effect cannot be excluded. A randomized controlled cross-over feeding trial in eight patients with Crohn's disease was primarily performed to assess the effect of 3-week exposure to moderate or low-FODMAP intake on fecal microbiota. 18 However, symptom levels in the patients did significantly fall, albeit from low levels as the patients were not selected on the basis of having functional gastrointestinal symptoms. Further randomized controlled trials are desirable.
Effect of increasing FODMAP intake. The final aspect is whether increasing FODMAP intake, specifically with oligosaccharides for their putative prebiotic effect, is of value in patients with IBD. It was noted previously that patients with Crohn's disease tended to eat fewer fructans than did healthy controls. In a pilot study, supplemental fructans (fructo-oligosaccharides) had promising anti-inflammatory effects, 19 but a well-powered subsequent study had no impact on inflammation and induced greater symptoms. 20 The interpretation of those results is confounded by the fact that background diets were not assessed for prebiotic intake. High doses of inulin (24 g/d) were evaluated in a blinded cross-over study of 20 patients with pouch inflammation. 21 While symptoms did not improve, inflammatory activity in the pouch did. Hence, the value of supplementing prebiotic oligosaccharides, either as supplements per se or by food choice warrants further study.
Risks of a low-FODMAP diet in symptomatic patients with quiescent IBD. The evidence is looking stronger that a low-FODMAP diet can provide symptomatic relief for patients with quiescent IBD and ongoing gastrointestinal symptoms. However, these benefits have to be balanced by potential adverse effects, as discussed by Staudacher in this journal. 24 There are three main areas of concern.
• The potential for a restrictive diet to compromise nutritional state is particularly important in this patient group, where undernutrition is very common. 21 The diet should be delivered to the patient by a dietitian, who would pay particular attention to ensuring adequate energy, fiber, and calcium intake.
• The effect of reducing FODMAP intake on intestinal inflammation must be considered seriously, as currently the information on this aspect is sketchy. In the randomized cross-over study of eight patients with Crohn's disease, 3-weeks' exposure to differing amounts of dietary FODMAPs had no effect on fecal calprotectin. 18 Likewise, Danish studies of patients with IBD have not found consistent changes in inflammatory activity. 16 In the study of patients with an ileal pouch, four of five with a low habitual FODMAP intake had pouchitis, whereas only two of seven who took moderate to high amounts of FODMAPs in their diet had pouchitis (P = 0.062). 17 Furthermore, supplemental inulin did improve inflammation in pouchitis as discussed previously. Hence, caution needs to be exercised.
• The effect of altering dietary FODMAP intake on fecal microbiota in healthy subjects and in patients with IBS or Crohn's disease was assessed in cross-over studies. There was a consistent "dysbiotic" pattern in association with the low FODMAP arm with considerably reduced relative abundance of strongly butyrate-producing Clostridium cluster XIVa and Akkermansia muciniphila of importance to the health of mucosa-associated microbiota and increase the mucus-degrading Ruminococcus torques. 18, 23 However, comparisons with the fecal microbiota during the baseline period where the subjects consumed their habitual diet suggested that most of the changes may have reflected more the prebiotic effect of higher oligosaccharide intake in the moderate FODMAP arm rather than the withdrawal of prebiotic oligosaccharides during the low FODMAP arm. Irrespective of these possibilities, it is imperative that the strict low-FODMAP diet be used only in the "induction" phase of delivering the dietary change (i.e., while the effect of FODMAPs is being assessed) and that responders undergo reintroduction to tolerance and that non-responders stop FODMAP restriction.
Conclusions
Evidence from unblinded and observational studies regarding the efficacy of reducing FODMAP intake for IBS-like symptoms in patients with quiescent IBD is compelling despite the lack of high-quality evidence. However, the risks associated with such dietary change have to be seriously considered in this patient group. Dietitian-led implementation of the diet is strongly recommended.
